Deficiency of complement C3a and C5a receptors does not prevent angiotensin II induced hypertension and hypertensive end organ damage.

Abstract

Complement activation may drive the pathology of hypertension through its effects on innate and adaptive immune responses, aside from direct effects on tissue integrity. Recently it was suggested that hypertension is a disease characterized by a decreased number of forkhead box protein 3 (Foxp3)+ regulatory T cells (Tregs) and that combined deficiency of the anaphylatoxin receptors C3aR (complement component 3a receptor) and C5aR1 (complement component 5a receptor) upregulates Tregs and heals hypertension and hypertensive end-organ damage. Using data from the European Renal cDNA Bank, renal single cell sequencing data and immunohistochemistry we found increased expression of C3aR, C5aR1 and Foxp3 in kidney biopsies of patients with hypertensive nephropathy. Expression of C3aR and C5aR1 was mainly found in myeloid cells and almost absent in lymphocytes. Next we aimed to determine whether C3aR or C3aR/C5aR1 double deficiency decreases blood pressure and hypertensive injury in Ang II infused mice. However, no difference was found for blood pressure, renal injury (albuminuria, glomerular and tubulointerstitial injury, inflammation) and cardiac injury (cardiac fibrosis, heart weight, gene expression) between C3aR KO and WT mice as well as C3aR/C5aR1 double KO respectively. Ang II as well as DOCA salt induced hypertension resulted in an increased number of Tregs in the kidney. This was valid in mice of the Balb/c and C57black strain. In summary, hypertensive nephropathy in patients is characterized by an increased expression of anaphylatoxin receptors and Tregs. However, deficiency of C3aR alone or C3aR and C5aR1 combined does not influence blood pressure or hypertensive end-organ damage in Ang II induced hypertension. Targeting the anaphylatoxin receptors C3aR alone or in combination with C5aR1 is not useful to treat cardiovascular disease in hypertension.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

German Research Foundation

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethic committee city of Hamburg

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

留言 (0)

沒有登入
gif